Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Ovid Therapeutics Inc (NASDAQ: OVID) closed at $1.63 up 8.67% from its previous closing price of $1.5. In other words, the price has increased by $8.67 from its previous closing price. On the day, 3.22 million shares were traded. OVID stock price reached its highest trading level at $1.66 during the session, while it also had its lowest trading level at $1.519.
Ratios:
For a deeper understanding of Ovid Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.28.
On October 09, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 116076136 and an Enterprise Value of 104236136. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.56 while its Price-to-Book (P/B) ratio in mrq is 2.59. Its current Enterprise Value per Revenue stands at 15.769 whereas that against EBITDA is -2.697.
Stock Price History:
The Beta on a monthly basis for OVID is 0.06, which has changed by 0.4298246 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $2.01, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 11.26%, while the 200-Day Moving Average is calculated to be 114.89%.
Shares Statistics:
For the past three months, OVID has traded an average of 2.79M shares per day and 1676760 over the past ten days. A total of 71.15M shares are outstanding, with a floating share count of 59.63M. Insiders hold about 16.27% of the company’s shares, while institutions hold 40.38% stake in the company. Shares short for OVID as of 1763078400 were 3499202 with a Short Ratio of 1.25, compared to 1760486400 on 3830348. Therefore, it implies a Short% of Shares Outstanding of 3499202 and a Short% of Float of 5.87.
Earnings Estimates
. The current rating of Ovid Therapeutics Inc (OVID) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.41 and -$0.49 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.36, with 6.0 analysts recommending between -$0.22 and -$0.65.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $7.08M, while the lowest revenue estimate was $6.5M, resulting in an average revenue estimate of $6.62M. In the same quarter a year ago, actual revenue was $566k
